https://lamintang.org/journal/index.php/ijcims <p>International Journal of Clinical Inventions and Medical Sciences (IJCIMS) provide a valuable platform for academicians, scholars, researchers and students to share their knowledge, ideas, development and insights of the most up-to-date research that focuses on the area of Medical/Biomedical Research, Preclinical Research and Clinical Research.</p> <p>IJCIMS published in English and twice a year (March and September).</p> Lamintang Education and Training Centre, in collaboration with the International Association of Educators, Scientists, Technologists, and Engineers (IA-ESTE) en-US International Journal of Clinical Inventions and Medical Sciences (IJCIMS) 2721-4737 <p>The copyright to this article is transferred to International Journal of Clinical Inventions and Medical Science (IJCIMS) if and when the article is accepted for publication. The undersigned hereby transfers any and all rights in and to the paper including without limitation all copyrights to IJCIMS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.</p> <p>We declare that:<br>1. This paper has not been published in the same form elsewhere.<br>2. It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.<br>3. A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.</p> <p>Furthermore, I/We hereby transfer the unlimited rights of publication of the above mentioned paper in whole to IJCIMS. The copyright transfer covers the right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature. The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.</p> <p>Retained Rights/Terms and Conditions<br>1. Authors retain all proprietary rights in any process, procedure, or article of manufacture described in the work.<br>2. Authors may reproduce or authorize others to reproduce the work or derivative works for the author’s personal use or for company use, provided that the source and the IJCIMS copyright notice are indicated, the copies are not used in any way that implies IJCIMS endorsement of a product or service of any employer, and the copies themselves are not offered for sale.<br>3. Although authors are permitted to re-use all or portions of the work in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use.</p> <p>The authors agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments to the editor can be added at the "Comments for the Editor").</p> https://lamintang.org/journal/index.php/ijcims/article/view/936 <p><em>Vaccinium bracteatum Thunb</em>. (VB) is a species of Vaccinium with a high flavonoid content and broad pharmacological potential, including antioxidant, anti-inflammatory, and neuroprotective activity. This study aims to isolate and characterize the main bioactive compounds from VB leaf water extract, as well as to develop and validate analytical methods for quantification of marker compounds as the basis for standardization of extracts. VB leaves are collected from various locations in South Korea and extracted using the aqueous extraction method. The compounds were then separated through silica gel column chromatography and HPLC preparations, and identified using UV-Vis, FTIR, 1D/2D NMR, and LC-MS/MS. HPLC-PDA AND LC-MS/MS methods were validated according to ICH guidelines (linearity, accuracy, precision, LOD, LOQ, specificity). The isolation results showed five main compounds: the flavonoids orientin (2.35%) and isoorientin (1.87%), phenolic acid vanillic acid (0.95%) and protocatechuic acid (1.12%), as well as the glycoside (0.78%). Validation of the analytical method showed a linearity of R² &gt; 0.999, an accuracy of 98.9–101.2%, a precision of &lt;2%, and a low LOD/LOQ, supporting the sensitive quantification of major and minor compounds. Spectroscopic and LC-MS/MS characterizations confirm the chemical structure of the compounds, confirming the purity of the isolate. These findings provide a scientific basis for the standardization of VB leaf extracts, supporting the development of herbal or nutraceutical products based on flavonoids and glycosides. Further research is recommended to explore in vivo activity, minor metabolite interactions, as well as the relationship of biosynthetic gene expression with phytochemical profiles to maximize the therapeutic potential of VB.</p> Praneet Chalidabhongse Won-Kyo Im Dong-Wan Lee Suttajit Tinakon Copyright (c) 2026 International Journal of Clinical Inventions and Medical Sciences (IJCIMS) https://creativecommons.org/licenses/by-sa/4.0 2026-03-18 2026-03-18 8 1 1 13 10.36079/lamintang.ijcims-0801.936